The ECJ has clarified how the "meaningful information" required under the General Data Protection Regulation (GDPR) on automated decisions based on score values should be structured (Case C-203/22).

Evolent Health, Inc. (NYSE ... Gain an edge in your investment decisions with InvestingPro’s in-depth analysis and exclusive insights on EVH. Our Pro platform offers fair value estimates ...

Exclusive: Dean Imperial's latest film will debut in the Narrative Spotlight section of the Austin festival. One of those films looking to make its mark on festivalgoers is Dean Imperial’s ...

In one of many sweeping changes to the functioning of the federal government, reports suggest that President Trump plans to take control over yet another independent agency, the U.S. Postal Service.

Founders know the mantra: make data-driven decisions. In recent years, the scientific approach to nurturing start-ups—developing hypotheses, collecting evidence that either supports or refutes ...

Enter: my five go-to prompts that guide me when I feel unsure about how to make a decision. Using decision-making frameworks and tools has helped me manage stress, feel less rushed, and stay more ...

Operator Welcome to the Evolent earnings conference call for the ... a number of Performance Suite renegotiations, we had a 100% logo renewal rate for our top customers in 2024, which together ...

ARLINGTON, Va. (AP) — ARLINGTON, Va. (AP) — Evolent Health Inc. (EVH) on Thursday reported a loss of $22.8 million in its fourth quarter. The Arlington, Virginia-based company said it had a ...

Oppenheimer analyst Michael Wiederhorn maintained a Buy rating on Evolent Health (EVH – Research Report) today and set a price target of $18.00. The company’s shares closed yesterday at $10.71.

Dedicated employee costs primarily include project management and technology staff costs needed to migrate acquired businesses to Evolent's integrated technology platform and costs related to the ...

CEO Seth Blackley noted Evolent Health achieved $2.55 billion in revenue for 2024, reflecting a 30% growth over the prior year, and $160.5 million in adjusted EBITDA at the low end of the guidance ...